login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Boston Scientific launches Ingenio and Advantio family of pacemakers in Europe


Wednesday, 11 Apr 2012 10:29

Boston Scientific has announced CE mark approval and European market launch of its Ingenio and Advantio pacemakers and  Invive cardiac resynchronisation therapy pacemakers (CRT-P). Marc Burban performed one of the first implants of the Ingenio on the first week of April at the Nouvelles Cliniques Nantaises in Nantes, France. 


“The Ingenio device enables physicians to treat pacemaker patients with an advanced and comprehensive set of therapies,” said Burban. “The new RightRate pacing is easy to optimise and is designed to provide needed heart rates for patients to help them feel less fatigued during physical activity.”

“The Ingenio family of pacemakers represents a significant investment in long-term innovation for pacing technologies and defines a new era of pacing for our company,” said Joe Fitzgerald, senior vice president and president of the Boston Scientific Cardiac Rhythm Management group. “In addition, we expect to launch a series of devices with expanded capabilities, that would include remote monitoring, advanced heart failure diagnostics and compatibility with magnetic resonance imaging systems - all designed to provide innovative new features for patient health and well-being.”


The Ingenio and Advantio pacemakers feature RightRate pacing technology designed to treat chronotropic incompetence. RightRate employs Boston Scientific’s minute ventilation sensor, the only sensor clinically proven to restore chronotropic competence, and adds programming options to promote ease of use and in-clinic time savings.


The Ingenio and Advantio pacemakers are currently under review by the US Food and Drug Administration (FDA), and are currently not available for sale in the United States.




Add New Comment

Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

First leadless pacemaker approved in the USA
Wednesday, 06 Apr 2016
Medtronic has announced it has received US Food and Drug Administration (FDA) approval for its Micra Transcatheter Pacing System (TPS). The leadless device, which is 93% smaller than conventional ... First leadless pacemaker approved in the USA

Presence of a wide and large S-wave in lead I is a powerful predictor of life-threatening ventricular arrhythmias in Brugada Syndrome patients
Wednesday, 30 Mar 2016
New research published in the Journal of the American College of Cardiology indicates that a wide/and or large S-wave in lead I is a powerful predictor of life-threatening ventricular arrhythmias in B... Presence of a wide and large S-wave in lead I is a powerful predictor of life-threatening ventricular arrhythmias in Brugada Syndrome patients

Features


Ventricular tachycardia ablation in Chagas disease
Friday, 13 May 2016
Guilherme Fenelon (Sao Paulo, Brazil) overviews the role of ablation of ventricular tachycardia in Chagas disease. He says: catheter ablation in Chagas disease remains a “challenging procedure,” ... Ventricular tachycardia ablation in Chagas disease

How innovation can unleash tremendous growth in the $3.4 billion AF ablation market
Monday, 29 Feb 2016
Shlomo Ben-Haim (London, UK), a professor of medicine and serial entrepreneur in the medical device industry, examines the drivers of expansion of the atrial fibrillation (AF) ablation market, the ... How innovation can unleash tremendous growth in the $3.4 billion AF ablation market

Profiles


George Van Hare
Wednesday, 04 May 2016
George Van Hare (The Louis Larrick Ward professor of Pediatrics and director, Division of Pediatric ... George Van Hare

Jonathan Kalman
Monday, 18 Jan 2016
A leading heart rhythm expert in Australia, Jonathan M Kalman directs both clinical and research ... Jonathan Kalman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions